Mavacamten
Mavacamten is the medicine inside Camzyos. The US label describes it as a reversible blocker of cardiac myosin, a protein of the heart muscle. The label gives its indication as symptomatic obstructive hypertrophic cardiomyopathy: for adults with class II-III symptoms in the older label version read, and for adults and pediatric patients who weigh at least 30 kg in the latest version read. A boxed warning says it can cause heart failure, and it can be obtained only through a restricted safety program. The atlas holds no trial results for it.
Also called Camzyos
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2600867. FDA application NDA214998, brand name Camzyos. The mechanism comes from version 8 of the label in the openFDA record (a reversible, allosteric blocker acting selectively on cardiac myosin). Version 9 on DailyMed, effective 30 September 2026, was the latest read; its indication wording differs from version 8, and the Drugs@FDA record lists an efficacy supplement approved on the same date, though it does not say what that supplement changed.
Trials at a glance
The figures count the 7 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 7
- Phase 3 or 4
- 6
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Not yet recruiting | Enrolling by invitation | Completed | Terminated | All statuses |
|---|---|---|---|---|---|
| Phase 2/3 | 0 | 0 | 1 | 0 | 1 |
| Phase 3 | 1 | 0 | 2 | 1 | 4 |
| Phase 4 | 1 | 1 | 0 | 0 | 2 |
| All phases | 2 | 1 | 3 | 1 | 7 |
Conditions these trials study
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- A reversible, allosteric blocker acting selectively on cardiac myosin (US drug label, version 8).
Claims and evidence
Context Adults, and in the latest label also pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Camzyos
- Recipient
- Mixed recipients
- Population
- People with symptomatic obstructive hypertrophic cardiomyopathy. The openFDA copy of the label (version 8, effective 2025-04-17) names adults with symptomatic New York Heart Association (NYHA) class II-III disease. The DailyMed label (version 9, effective 2026-09-30) names adults and pediatric patients who weigh at least 30 kg.
- Care setting
- Prescription medicine under a restricted program; the label records state the program but not a care setting
- Geography
- United States (labeling approved by the US Food and Drug Administration)
- Life stage
- Adults in version 8 of the label; adults and pediatric patients who weigh at least 30 kg in version 9. The records give no other age limit.
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (regulatory and labeling statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Symptomatic obstructive hypertrophic cardiomyopathy (label indication)
- Excluded
- None stated
The Camzyos label carries a boxed warning of the risk of heart failure. It says Camzyos lowers the left ventricular ejection fraction and can lead to heart failure from weakened pumping (systolic dysfunction). Version 8 of the label (openFDA) states that the medicine can be obtained only through a restricted safety program set up under a Risk Evaluation and Mitigation Strategy, and version 9 (DailyMed) describes the same restricted program.
Applies to Mixed recipients Adults, and in the latest label also pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Camzyos
- Certainty method
- Not assessed
- Limitations
- This claim records the headline of the boxed warning only. The warning also covers ejection fraction checks and interacting medicines, which are not recorded here. The DailyMed label is cite only, so its wording is paraphrased. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
Supports Camzyos drug label (openFDA record, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 8)
- Locator
- results[0].boxed_warning[0]
- How it applies
- Boxed warning in label version 8.
- Retrieved
- Source effective date
- 2025-04-17
- Source state
- Current
- Version fingerprint
78fe53bfe25e2c043bd661aad42fa246457021432aaeb27721c641e8f2e639fb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, https://open.fda.gov/license/; licence page fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.
-
Supports Camzyos drug label (DailyMed SPL, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9)
- Locator
- Boxed warning
- How it applies
- Boxed warning in label version 9.
- Retrieved
- Source effective date
- 2026-09-30
- Source state
- Current
- Version fingerprint
e081aa570e068b67ff424c4b28bfd0d79e871a2d88c6c4e0744666549f31fb6c- Reuse basis
- DailyMed labeling is the manufacturer's FDA-approved labeling. The reuse terms of the DailyMed pages were not read, so this atlas treats the source as cite only: facts are stated in its own words with the citation and link, and only the hash of the bytes is kept.
-
Supports Camzyos drug label (DailyMed SPL, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9)
- Locator
- Boxed warning, restricted program
- How it applies
- Restricted program in label version 9.
- Retrieved
- Source effective date
- 2026-09-30
- Source state
- Current
- Version fingerprint
e081aa570e068b67ff424c4b28bfd0d79e871a2d88c6c4e0744666549f31fb6c- Reuse basis
- DailyMed labeling is the manufacturer's FDA-approved labeling. The reuse terms of the DailyMed pages were not read, so this atlas treats the source as cite only: facts are stated in its own words with the citation and link, and only the hash of the bytes is kept.
The US Food and Drug Administration lists Camzyos (mavacamten) under new drug application NDA214998. The openFDA record names the applicant as BRISTOL and lists the original submission as approved on 28 April 2022 in the class Type 1 - New Molecular Entity. The copy of the label in the openFDA label record (version 8, effective 17 April 2025) says Camzyos is indicated for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms. The label on DailyMed (version 9, effective 30 September 2026) states the indication for adults, and for pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy. The openFDA application record lists supplement 13, of class Efficacy, as approved on 30 September 2026, the same date as the DailyMed label.
Applies to Mixed recipients Adults, and in the latest label also pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Camzyos
- Certainty method
- Not assessed
- Limitations
- An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The two label versions state the indication differently and the openFDA copy is the older one; the atlas gives both and treats the DailyMed text as the latest read. The records do not say what supplement 13 changed, so the link between that supplement and the new wording is an inference from the matching date. The DailyMed label is cite only, so its wording is paraphrased. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
- Last checked
- 2026-10-30
- Next evidence check due
- Not scheduled
Sources and citations (13)
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].application_number
- How it applies
- Application number.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].sponsor_name
- How it applies
- Applicant.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].brand_name
- How it applies
- Brand name.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].products[0].active_ingredients[0].name
- How it applies
- Active ingredient.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[0].submission_type
- How it applies
- Original submission.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[0].submission_status
- How it applies
- Status of the original submission (AP is approved).
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[0].submission_status_date
- How it applies
- Date of the original approval, written as eight digits.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[0].submission_class_code_description
- How it applies
- Class of the original submission.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[3].submission_number
- How it applies
- Supplement number.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[3].submission_status_date
- How it applies
- Date of supplement 13, written as eight digits.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports FDA drug application NDA214998 (openFDA Drugs@FDA record)
- Locator
- results[0].submissions[3].submission_class_code_description
- How it applies
- Class of supplement 13.
- Retrieved
- Source effective date
- 2026-10-29
- Source state
- Current
- Version fingerprint
972f8a2e87f79cde9dfd1433812aab8b0f3c4eb37dccdf57d7c9130e1df8dd71- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
-
Supports Camzyos drug label (openFDA record, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 8)
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Indication in label version 8 (older copy).
- Retrieved
- Source effective date
- 2025-04-17
- Source state
- Current
- Version fingerprint
78fe53bfe25e2c043bd661aad42fa246457021432aaeb27721c641e8f2e639fb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/terms/, https://open.fda.gov/license/; licence page fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The label text is the manufacturer's labeling as FDA publishes it; check the openFDA documentation for a not-in-the-public-domain warning before quoting beyond short passages. The raw file is committed in the atlas repository.
-
Supports Camzyos drug label (DailyMed SPL, set id 669c936b-3ee6-4e36-8a22-79dd11b1255b, version 9)
- Locator
- Section 1, Indications and Usage
- How it applies
- Indication in label version 9 (latest read).
- Retrieved
- Source effective date
- 2026-09-30
- Source state
- Current
- Version fingerprint
e081aa570e068b67ff424c4b28bfd0d79e871a2d88c6c4e0744666549f31fb6c- Reuse basis
- DailyMed labeling is the manufacturer's FDA-approved labeling. The reuse terms of the DailyMed pages were not read, so this atlas treats the source as cite only: facts are stated in its own words with the citation and link, and only the hash of the bytes is kept.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
CAMZYOS
No label from the application holder was found in the openFDA label dataset for application NDA214998. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact US label indication: symptomatic obstructive hypertrophic cardiomyopathy: Hypertrophic cardiomyopathy
Applies to Mixed recipients Adults, and in the latest label also pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Camzyos
The US Food and Drug Administration lists Camzyos (mavacamten) under new drug application NDA214998. The openFDA record names the applicant as BRISTOL and lists the original submission as approved on 28 April 2022 in the class Type 1 - New Molecular Entity. The copy of the label in the openFDA label record (version 8, effective 17 April 2025) says Camzyos is indicated for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms. The label on DailyMed (version 9, effective 30 September 2026) states the indication for adults, and for pediatric patients who weigh at least 30 kg, who have symptomatic obstructive hypertrophic cardiomyopathy. The openFDA application record lists supplement 13, of class Efficacy, as approved on 30 September 2026, the same date as the DailyMed label.Limitations. An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The two label versions state the indication differently and the openFDA copy is the older one; the atlas gives both and treats the DailyMed text as the latest read. The records do not say what supplement 13 changed, so the link between that supplement and the new wording is an inference from the matching date. The DailyMed label is cite only, so its wording is paraphrased. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
Registry trials 7
Record details
- Record id
cardio:mavacamten- Content hash
e8d7d1230f254f7964fbfc111b530de1f55166f3857d87db00b95596a4b744d5